Financial Data and Key Metrics Changes - Revenue increased to JPY1,603.7 billion, up 5.6% year-on-year, achieving 102.7% of the full year forecast [10] - Core operating profit was JPY184.6 billion, down by 35.6% year-on-year, but exceeded the full year forecast at 112.6% [10] - Operating profit decreased to JPY25.5 billion, down by 80.8% year-on-year, and profit decreased to JPY17 billion, down 82.7% year-on-year [11] Business Line Data and Key Metrics Changes - XTANDI sales increased to JPY750.5 billion, up by about JPY90 billion or 14% year-on-year [12] - PADCEV global sales increased to JPY85.4 billion, up 92% year-on-year, realizing nearly twofold growth [13] - XOSPATA global sales increased to JPY55.1 billion, up 18% year-on-year [16] - VEOZAH sales reached JPY7.3 billion, progressing in line with the forecast [16] - IZERVAY sales reached JPY12.1 billion, exceeding the full year forecast [18] Market Data and Key Metrics Changes - Commercial lives covered for VEOZAH expanded to 50% as planned by the end of March [17] - The number of launched countries for PADCEV increased to 36 in total [15] Company Strategy and Development Direction - The company aims to maximize product value through active life cycle management and indication expansion [41] - The focus is on sustainable growth through strategic product launches and pipeline development [22][44] - The company plans to review management resource allocation and implement stringent cost control while securing investment for future growth [46][79] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges due to the entry of generics and the impact of the Inflation Reduction Act on XTANDI sales [40][49] - The company is optimistic about the growth of strategic products like PADCEV and IZERVAY, despite some setbacks [41][62] - Future sales growth is expected to significantly outpace expenses, contributing to profits [66] Other Important Information - The company has revised its peak sales forecast for IZERVAY from JPY300 billion - JPY500 billion to JPY150 billion - JPY250 billion [61] - The definition of core basis has been updated to better reflect profitability [74] Q&A Session Summary Question: Review of CSP assumptions for FY 2025 - Management confirmed that the performance goals in CSP 2021 will remain unchanged, but they will continue to analyze the numbers and scenarios [90][91] Question: Impact of J-Code approval on IZERVAY sales - Management highlighted that the permanent J-Code will simplify reimbursement procedures, expanding the customer base, and emphasized the importance of launching IZERVAY in additional markets [92][93] Question: Concerns regarding mirabegron generics - Management acknowledged the ongoing legal situation but noted that the injunction by the appeals court is temporary and its duration is unclear [95] Question: Journey towards improving core OP margin - Management indicated that growth in products like PADCEV and IZERVAY is expected to positively impact the OP margin [97][99] Question: Dividend strategy and future increases - Management expressed a commitment to stable dividend increases while being cautious about future profitability, especially with XTANDI's patent expiration approaching [102][103]

Financial Data and Key Metrics Changes - Revenue for Q3 FY 2023 increased to ¥1.1891 trillion, up 2.1% year-on-year, but was behind the full-year forecast revised in Q2 [8] - Core operating profit decreased to ¥149.6 billion, down 36% year-on-year, primarily due to the impact of the acquisition of Iveric Bio and LEXISCAN generics [9] - Operating profit was ¥74.1 billion, down 59.1% year-on-year, with profit decreasing to ¥50.3 billion, down 65.3% year-on-year [10] Business Line Data and Key Metrics Changes - XTANDI global sales increased to ¥460 billion, up 9% year-on-year, in line with the revised full-year forecast [11] - XOSPATA global sales increased to ¥41.3 billion, up 14% year-on-year, also in line with the revised full-year forecast [14] - PADCEV global sales increased substantially to ¥55.6 billion, up 68% year-on-year, in line with the revised full-year forecast [15] - VEOZAH year-to-date sales were ¥3.6 billion, with full-year forecast revised downward to $50 million due to lower-than-expected demand [20][24] Market Data and Key Metrics Changes - In the U.S., XTANDI received an additional indication approval based on EMBARK study results, expected to contribute to future sales [12] - PADCEV's approval for additional indications in the U.S. and Europe is anticipated to drive significant sales contributions in FY 2024 and beyond [16][44] - VEOZAH's market access expanded to about 35% lives covered as of December, with expectations to exceed 50% by the end of FY 2023 [25] Company Strategy and Development Direction - The company aims to maximize the product value of VEOZAH while carefully examining the timing for investments to ensure the greatest return [40] - Astellas is focusing on sustainable growth, with expectations for revenue and profit increases in FY 2024, setting FY 2023 as a turning point [64] - The company is enhancing its DTC activities to increase awareness and drive demand for VEOZAH and IZERVAY [29][35] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that VEOZAH's demand is trailing internal expectations due to HCPs' perceptions of payer coverage [21][24] - The company is optimistic about the future growth of IZERVAY, driven by upcoming milestones such as the permanent J-code and label update [35] - Management expects to achieve sustainable growth from FY 2024 onward, with a focus on key strategic products [64] Other Important Information - The company has made significant progress in the development of key strategic products, including the launch of VEOZAH and IZERVAY [62] - Astellas is actively working on open innovation initiatives to enhance R&D capabilities and collaborations with academic institutions [60] Q&A Session Summary Question: What is the biggest reason behind the lack of progress in payer coverage for VEOZAH? - Management clarified that payer coverage has progressed to 35% and is on track to exceed 50% by the end of FY 2023, but HCPs' perceptions lag behind this progress [68][70] Question: Why is there a delay in patients visiting HCPs despite increased awareness from DTC activities? - Management noted that the time for women to get appointments with HCPs is longer than anticipated, now estimated at three to four months [73] Question: What percentage of physicians consider the coverage sufficient? - Management is currently researching this question and will provide details in the next quarterly call [75] Question: Will the payer coverage conditions be simplified? - Management indicated that they are not changing their approach to payers at this time and are confident in achieving the planned coverage [81] Question: What is the update on the label for IZERVAY? - Management confirmed that a submission for a label update was made in January, aiming to lift the restriction on administration duration and extend the administration schedule [82][85]

Q2/FY2023 FINANCIAL RESULTS ENDED SEPTEMBER 30, 2023 Naoki Okamura President and CEO Astellas Pharma Inc. November 1, 2023 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the informati ...

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu Shitaka - Chief Scientific Officer Tadaaki Taniguchi - Chief Medical Officer Claus Zieler - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Naomi Kumagai - Mitsubishi UFJ Morgan Stanle ...

Q3/FY2022 FINANCIAL RESULTS ENDED DECEMBER 31, 2022 Minoru Kikuoka Chief Financial Officer (CFO) Astellas Pharma Inc. February 6, 2023 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of t ...

Astellas Pharma Inc. (OTCPK:ALPMF) Q3 2022 Earnings Conference Call October 31, 2022 4:00 AM ET Company Representatives Kenji Yasukawa - Chief Executive Officer Yoshitsugu Shitaka - CScO, Chief Scientific Officer Minoru Kikuoka - Chief Financial Officer Tadaaki Taniguchi - Chief Medical Officer Bernie Zeiher - Chief Medical Officer Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Motoya Koutani - Nomura Securities Fumiyoshi Sakai ...

Q1/FY2022 FINANCIAL RESULTS ENDED JUNE 30, 2022 Minoru Kikuoka Chief Financial Officer (CFO) Astellas Pharma Inc. August 1, 2022 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's current assumptions and beliefs in light of the inf ...

Astellas Pharma, Inc. (OTCPK:ALPMF) Q1 2022 Results Conference Call July 30, 2021 3:00 AM ET Company Participants Naoki Okamura - CSO & CFO Mike Kitagawa - Senior VP of Development Project Management Yukio Matsui - Chief Commercial Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Kazuaki Hashiguchi - Daiwa Securities Seiji Wakao - JPMorgan Fumiyoshi Sakai - Credit Suisse Shinichiro Muraoka - Morgan Stanley Naoki Okamura Hello, everyone. I'm CSO and CFO at Astellas Pharma Inc. I'm Naoki Ok ...

Q1/FY2021 FINANCIAL RESULTS ENDED JUNE 30, 2021 Chief Strategy Officer and Chief Financial Officer Naoki Okamura Executive Vice President, Astellas Pharma Inc. July 30, 2021 CAUTIONARY STATEMENT REGARDING FORWARDLOOKING INFORMATION 2 In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas Pharma. These statements are based on management's curre ...

Astellas Pharma, Inc. (OTCPK:ALPMF) Q4 2021 Earnings Conference Call April 27, 2021 1:00 AM ET Company Participants Kenji Yasukawa - President & CEO Naoki Okamura - Corporate EVP, Chief Strategy Officer and CFO Yukio Matsui - Chief Commercial Officer Bernie Zeiher - Chief Medical Officer Conference Call Participants Hidemaru Yamaguchi - Citigroup Securities Kazuaki Hashiguchi - Daiwa Securities Fumiyoshi Sakai - Credit Suisse Securities Seiji Wakao - JP Morgan Securities Motoya Kohtani - Nomura Securities S ...